Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The retinoblastoma (Rb) protein is a known tumor suppressor that inhibits E2F transcription factors, regulating cell cycle progression.
• The physiological role of the hyper-phosphorylated, non-E2F1-interacting form of Rb has remained largely unknown.
• Understanding Rb's function beyond E2F inhibition is critical for cancer research.

Purpose of the Study:

• To investigate the physiological role of hyper-phosphorylated retinoblastoma (Rb) protein.
• To determine if Rb interacts with and regulates mTORC1 or mTORC2 signaling pathways.
• To elucidate the mechanism by which Rb influences Akt activation and drug sensitivity.

Main Methods:

• Co-immunoprecipitation assays to detect protein-protein interactions between Rb and mTOR components.
• Western blotting to assess protein phosphorylation levels and pathway activation (e.g., Akt).
• Cellular assays measuring sensitivity to chemotherapeutic drugs under various genetic and pharmacological manipulations.

Main Results:

• Hyper-phosphorylated Rb directly binds to and suppresses the function of mTORC2, but not mTORC1.
• Rb interacts with Sin1, blocking Akt access to mTORC2, leading to reduced Akt activation and increased sensitivity to chemotherapy.
• Inhibition of Rb phosphorylation (via cyclin D depletion or CDK4/6 inhibitors) releases mTORC2 suppression, elevating Akt activation and conferring chemoresistance.

Conclusions:

• The hyper-phosphorylated form of Rb plays a direct role in suppressing mTORC2 signaling.
• Rb-mediated suppression of mTORC2 influences cellular sensitivity to chemotherapeutic agents.
• Targeting Rb phosphorylation or combining CDK4/6 and Akt inhibitors offers a potential therapeutic strategy for Rb-proficient cancers.